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essary duplication of effort must be eliminated. However, doing so is difficult due to 
the current culture of data protectionism and a lack of suitable software that enables 
convenient and useful sharing of the intermediate results. ApproAch: Building on 
our previously published reviews of software for systematic review and trial analyt-
ics, the talk identifies the technical and cultural challenges to be met. We propose 
that a web-based solution enabling the global research community to contribute 
their intermediate results in exchange for access to the data contributed by others 
could rapidly gain momentum. Such a system would challenge data protectionism by 
greatly reducing the level of investment required for data acquisition. conclusion: 
A disruptive web-based system enabling a massively collaborative approach to sys-
tematic reviewing can make data protectionism obsolete and eliminate much of the 
effort required for future systematic reviews.
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Value-Based Pricing in tHe uK and Potential Patient access Hurdles 
to innoVatiVe drugs
Papadopoulou K., Grosvenor A.
PriceSpective, London, UK
The UK government plans to introduce value-based pricing (VBP) for medicines in 
England and Wales from January 2014, and one of the key tenets of the scheme is 
to improve patient access to new innovative drugs. This poster aims to explore the 
extent to which VBP is likely to achieve this goal. To meet this objective, an in-depth 
review of available literature (including white papers from key stakeholders and sci-
entific publications) was conducted. Targeted interviews with five leading thought-
leaders in the implementation of VBP were also conducted to support analysis. 
Research identified a number of areas of uncertainty in VBP implementation that 
could detrimentally impact patient access to new drugs. First, the timeline for the 
VBP negotiation process remains unclear. Currently, it takes NICE on average 48 
weeks to issue guidance on a single technology appraisal, which could be extended 
if a technology is not considered cost-effective. Under VBP, manufacturers will still 
be required to negotiate their price with the Department of Health if the calculated 
VBP price by NICE is unfavorable, and the VBP HTA methodology itself could be more 
complex than the current cost-per-QALY approach. Protracted negotiations could 
also delay access in Scotland and Northern Ireland. Equally, manufacturers may 
postpone launch in the UK if they consider VBP a threat in their price corridor in 
other markets. Finally, it is not clear if additional regional or local level negotiations 
will take place, which could further delay access. In conclusion, although there is 
potential for the new adjustable QALY threshold (which remains to be confirmed) 
to foster innovation, the ability of the new VBP process to expedite patient access 
remains uncertain.
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a cHoice of Business for tHe PHarmaceutical industry “seguro 
PoPular” in mexico
Vilchis S.
Sistema de Proteccion Social en Salud Mexico, Mexico, Mexico
A choice of business for the pharmaceutical industry “Seguro Popular” in Mexico. 
Abstract Mexico has various providers of health services each one determined to 
a sector of the population where we can find the Mexican Social Security Institute 
(IMSS) that is specifically for workers in the private sector employees and their 
families, the Institute for security and services social of the State workers (ISSSTE) 
for workers in the service of the State or public sector and their families starting 
2003 ushered to the Seguro Popular that extends to the population without social 
security or in State of helplessness in these three mentioned health are emerg-
ing as institutions providing health services larger Mexico insomuch that by 2013 
the Seguro Popular has approximately 54 million affiliates number of successful 
membership in less than 10 years in a country where there is little more than 110 
million of people Seguro Popular is placed, on par with the historic and hegemonic 
IMSS, as the largest buyer of drugs, aware of this are his consumption figures that 
since 2008 has been made public, in such data can find that from 2008 to 2012 they 
have bought 1,241,637,748.68 US Dlls only in drugs consumption regularly since the 
Seguro Popular has several portfolios of services where separate regular conditions 
of sufferings of low frequency and high cost and conditions of very low frequency 
and high cost for children under 5 years who in turn have specific budgets.
disease-sPecific studies 
gastrointestinal disorders – clinical outcomes studies
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HosPital mortality in england, tHe netHerlands, and sPain
Wasserman M., Jones C., Roberts G., Latif F.
Double Helix Consulting, London, UK
objectives: Increasing rates of Clostridium Difficile Infection (CDI), a hospital-acquired 
infection, has stimulated a number of financial incentives and government spon-
sored initiatives to quell the spread of the disease. Previous research has shown the 
impact of CDI on hospital length of stay to attempt to quantify the resource impli-
cations. The purpose of this study is to evaluate the impact of CDI on in-hospital 
mortality. Methods: Data were obtained from national hospital episode databases 
in England, The Netherlands, and Spain. Only patients over the age of 50 and those 
diagnosed with diabetes, chronic kidney disease, heart failure, and chronic obstructive 
pulmonary disease (COPD) were included in the analysis. Cases of CDI were stratified 
between hospital-onset and community-onset cases. Only those that were assumed 
to be hospital-onset were included in the analysis. A logistical regression was used to 
predict the relative effect hospital-onset CDI had on in-hospital mortality. A number 
of covariates were controlled for including: age, sex, comorbidities, and length of stay 
but varied between countries depending on the availability of data. results: Patients 
with hospital-onset CDI had an overall higher mortality rate compared to those who 
horizontal differentiation), which is often cited (beside R&D costs) as the second barrier 
to entry to the branded market. Here, we have discussed several examples of Cournot 
model within various ATC4 groups and jurisdictions. We have also critically examined 
preponderance of »me-too« entries, particularly in the light of an R&D investment of 
the branded firms. Historically, »me-too« drugs are more ubiquitous than often real-
ized by regulatory agencies, payers, and also the pharmaceutical industry itself. This 
unfortunately presents an inefficient use of resources as the breakthough innovation 
is nowadays, in the time of austerity measures, a real necessity. The models that would 
give incentives to the industry to invest in R&D for breaktrough therapies are possible 
and would not only contribute to optimization of societal welfare but would also in 
the long run increase an R&D productivity of branded firms.
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cHallenges tHat lie aHead
Walker R.1, Mackenzie A.2
1PriceSpective, London, UK, 2PriceSpective, Cambridge, MA, USA
This poster seeks to highlight the key challenges and opportunities surrounding patient 
access to innovative cell therapies in the EU5 and US. The findings are based on second-
ary research of commercialised cell therapies as well as primary research with payers 
in EU5 and US. Cell therapies have a unique opportunity to improve patient outcomes 
but face their own set of challenges due to being cell based. As many of these thera-
pies involve manipulation of the patients’ own cells before being reintroduced (e.g., 
ChondroCelect), the associated side effects are likely to be minimal. Other therapies 
(e.g., gene therapy, Glybera) involve the introduction of foreign genetic material but 
provide a potential long-term cure. However, there are some important challenges that 
must be assessed when considering how to commercialise such therapies. In the case of 
therapies where a patient’s cells are manipulated ex vivo, who bears the risk if the patient 
does not receive their individualised treatment? For those therapies that purport to cure 
disease, how much are health care systems willing to pay for them and what evidence 
would be required in order to justify a high price? Moreover, for all therapies, there is the 
uncertainty regarding access pathways: will cell therapies necessarily undergo an HTA 
evaluation to gain access in the EU? What are the criteria that will be used to determine 
whether such a therapy is deemed a product (and, hence, undergo an assessment like 
a regular biopharmaceutical) or a procedure (and likely bypass a national evaluation)? 
In conclusion, cell therapies face uncertainties in market access and funding due to 
unestablished pathways for the spectrum of interventions that fit under the cell therapy 
umbrella. Until frameworks have been put in place, each cell therapy should be assessed 
individually in order to determine likely pathway to patient access.
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suPPorting innoVation in areas of unmet medical need
Dionne P.A.1, Ali F.1, Grobler M.2
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New discoveries are a critical priority for the pharmaceutical industry, for which 
the primary aim should be to address unmet medical needs. However, the use of 
fixed cost-effectiveness (ICER) thresholds for health technology assessment (HTA) 
may tend to decrease incentives to innovate and affect future treatment options. 
This presentation highlights, using a case study, the impact of recent generic drug 
price policies on pharmaceutical innovation in the context of fixed ICER thresh-
olds and proposes a new consideration for the cost-effectiveness analysis (CEA). 
There is a direct causal relationship between HTA and the market price of a drug; 
in jurisdictions where HTA agencies apply fixed ICER thresholds as an important 
reimbursement listing criterion, the incremental cost of a new drug is expected to be 
proportional to its incremental benefit over the comparator. However, the compara-
tor price is subject to market forces or sudden policies and may change markedly 
affecting the cost-effectiveness assessment (e.g. where the comparator patent has 
expired). Since recent generic price regulations (e.g. 18% or 25% of the innovative 
price in Canada) increased the price gap between drugs’ generic and patented ver-
sions, it is harder to achieve a sufficient level of incremental benefits in order to 
offset incremental prices of new treatments. This analysis thus demonstrates that 
with recent changes in generic drug prices in Canada and other jurisdictions, even 
promising drugs will have challenges to show attractive ICERs. Traditional decision-
making process should be adapted to reflect these changes and to promote innova-
tion in therapeutic fields with unmet medical needs. A compromise would be to 
include the comparator’s patented price in the CEA instead of the generic drug in 
certain areas of unmet needs. By identifying the relevant disease areas, decison 
makers and HTA authorities could convey the importance of investing in these 
therapeutic areas to manufacturers.
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tHe exPanding scoPe of comParatiVe effectiVeness reViews requires 
collaBoratiVe information systems solutions
van Valkenhoef G.
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
bAckground: The scope of systematic reviews and health technology assessments 
is rapidly expanding due to increasing demand for more complex models that account 
for patient, treatment, and trial characteristics, network meta-analyses that include 
more interventions, and the growing number of clinical trials. By the year 2000, the 
effort required to publish a typical systematic review had already reached the thou-
sands of person-hours, which were predominantly spent on data acquisition tasks. 
Innovative solutions are required to prevent the costs of comparative effectiveness 
research from ballooning out of proportion. probleM: Typically only the end product 
of systematic reviewing, a report summarizing the evidence, is made widely avail-
able. However, capturing the intermediate results of literature searching, publication 
screening, and data extraction has the potential to greatly enhance the efficiency of 
future reviews. In the face of the increasing scope of systematic reviews, this unnec-
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literature review was performed to identify relevant randomized controlled trials 
(RCTs). Data were extracted on study design and patient characteristics. Endpoints 
concerning efficacy were evaluated using network meta-analyses. Clinical response 
was defined as a decrease in Mayo score of ≥ 30% and ≥ 3 points, accompanied by a 
decrease in rectal bleeding score of ≥ 1 point or rectal bleeding score of 0 or 1. Clinical 
remission was defined as a total Mayo score of 2 points or lower, with no individ-
ual subscore exceeding 1 point. Mucosal healing was defined as absolute subscore 
for endoscopy of 0 or 1. Bayesian network meta-analyses (NMA) were conducted 
to evaluate each efficacy endpoint for TNF-naïve patients at the end of induction. 
All analyses were conducted using the OpenBUGS software package. results: Six 
RCTs were identified from the literature. Similar clinical response was observed 
between the IFX and GOL treatment regimens (IFX 5mg: OR= 2.74, 95%Crl [1.48-5.1], 
IFX 10mg: 2.54 [1.37-4.73], GOL 200/100mg: OR= 1.7 [0.93-3.14], GOL 400/200mg: 1.95 
[1.05-3.58]) when compared to ADA 160/80mg. These similarities were also seen for 
mucosal healing (IFX 5mg: 2.66 [1.43-4.94], IFX 10mg: 2.57 [1.38-4.77], GOL 200/100mg: 
1.54 [0.83-2.85], GOL 400/200mg: 1.68 [0.91-3.10]). IFX demonstrated slightly greater 
clinical remission than GOL (IFX 5mg: 1.96 [0.80-4.65], IFX 10mg: 1.51 [0.61-3.62], GOL 
200/100mg: 1.55, 0.59-4.06], GOL 400/200mg: 1.47 [0.56-3.84]) when compared to ADA 
160/80mg. conclusions: The NMA allowed the estimation and comparisons of 
clinical response, remission, and mucosal healing of interventions for UC evaluated in 
different RCTs. The findings suggest that the greatest induction of response in moder-
ate to severe UC patients is most likely achieved with IFX and GOL compared to ADA.
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objectives: To evaluate the comparative long-term efficacy of approved bio-
logic treatments for ulcerative colitis (UC), with a focus on golimumab(GOL), 
adalimumab(ADA), and infliximab(IFX). Methods: A systematic literature review 
identified 4 randomized controlled trials (RCTs) assessing the efficacy of IFX (5mg, 
10mg), ADA (160/80/40mg) and GOL (100mg, 50mg) as maintenance treatment for 
moderate to severe UC. Data were extracted on study design and patient character-
istics. Endpoints concerning efficacy were evaluated using network meta-analyses 
(NMA) within a Bayesian framework. Analyses were conducted to evaluate sus-
tained response to therapy at both the mid-point (week 30/36) and completion 
(week 52/54/60) of each trial. An additional sub-analysis was conducted because 
the PURSUIT trial design included a re-randomization of induction responders 
to placebo, GOL 50mg or GOL 100mg. This sub-analysis was limited to patients 
who received an induction regimen of GOL 200/100mg followed by 100mg during 
the maintenance period and induction non-responders who received 100mg as 
per protocol. All analyses were conducted using the OpenBUGS software pack-
age. results: 4 RCTs were identified from the literature. Overall, IFX and GOL 
showed greater sustained response, remission and mucosal healing when compared 
to ADA 160/80/40mg. Between IFX and GOL, IFX doses showed greater remission at 
trial’s completion (IFX5mg OR= 2.04, 95%Crl 0.6-7.03; IFX10mg 1.96, 0.6-6.8; GOL50mg 
1.24, 0.4-3.9; GOL100mg 1.79, 0.6-5.4), response (IFX5mg 1.88,0.8-4.4; IFX10mg 1.73, 
0.7-4.1; GOL50mg, 1.38, 0.6-3.1; GOL100mg 1.45, 0.6-3.3) and mucosal healing (IFX5mg 
1.51,0.7-3.4; IFX10mg 1.53, 0.7-3.5; GOL50mg, 1.38, 0.6-3.3; GOL100mg 1.38, 0.6-3.2. 
During the sub-analyses, GOL100mg and both IFX doses demonstrated greater sus-
tained response and sustained remission when compared to ADA 160/80/40mg. 
Sustained mucosal response increased for IFX 5mg and IFX10mg but decreased for 
GOL100mg. conclusions: Based on indirect comparison of RCT evidence, IFX 
and GOL are more efficacious to induce and maintain long term response than ADA 
among moderate to severe UC patients.
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a systematic reView of antidePressants in irritaBle Bowel 
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objectives: To systematically identify and review published evidence on the efficacy 
of antidepressants (tricyclic antidepressants (TCA) and selective serotonin inhibi-
tors (SSRI)) for irritable bowel syndrome (IBS). Methods: A systematic search of the 
medical literature was conducted using PubMed, Embase, and Cochrane databases. 
Search terms included ‘irritable bowel syndrome’, ‘spastic colon’, ‘irritable colon’, 
‘functional diseases, colon’ and a mixture of agent terms – including antidepressants, 
tricyclic, and SSRIs. Randomised placebo-controlled trials evaluating the efficacy of 
antidepressants (SSRIs and TCAs) in adult patients with IBS were eligible for inclusion. 
Exclusion criteria included absence of placebo arm, patients< 18 years of age, and dual 
publication. results: A total of 628 unique titles and abstracts were retrieved; 579 
records were excluded upon title (or abstract) review and 31 upon full-text review. The 
final review included 17 studies, 10 reporting on TCAs, 6 on SSRIs, and 1 comparing 
both an SSRI and a TCA vs. placebo, and assessed the methodological compliance of 
each included study with that used in regulatory submissions. In these studies, the 
majority of patients had diarrhea, and only one study, (on SSRIs) reported specifically 
on IBS-C. Treatment duration ranged from 4-12 weeks. A range of outcomes were 
reported, most commonly global symptom relief, and improvements in abdominal 
pain/discomfort. Three studies reported on quality of life, while no studies reported 
specifically on treatment satisfaction. Most outcomes did not align well with those 
now required for FDA and EMA regulatory approval. Across all studies, patient drop-
outs were common, and reporting on per-protocol and intention-to-treat (ITT) popu-
lations varied and in many cases was not explicitly reported. conclusions: The 
evidence base was of low quality, making estimates of effect very uncertain. Data for 
the efficacy of antidepressants in IBS subtypes is especially limited. Further studies 
are required to support the off-label use of antidepressants in IBS-C.
did not have the disease, demonstrated by a crude relative risk of 6.06 in England 
(37.6% vs. 6.2%), 2.68 in The Netherlands (19.0% vs. 7.1%), and 1.97 in Spain (14.9% vs. 
7.5%). When controlling for covariates, predictive models found a considerable impact 
of hospital-onset CDI on mortality with odds ratios of 2.57 for England (p< 0.001), 
1.88 for The Netherlands (p< 0.001) and 1.33 for Spain (p< 0.001). conclusions: This 
research demonstrates the significant impact of CDI on hospital mortality and the 
need for more preventative measures within the hospital setting. Further research 
using death certificate data could improve the predictive results of models by ensur-
ing that causal effects of CDI are accurately accounted for.
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objectives: The inflammatory bowel diseases (IBD) are characterized by chronic 
inflammation of the gastrointestinal tract; the irritable bowel syndrome (IBS) is a func-
tional disorder (prevalence 10%-20%). They present overlapping symptoms, making 
diagnosis difficult in primary care. Endoscopy is the gold standard for IBD, but it often 
turns negative due to IBD’s low prevalence, it is expensive, uncomfortable and risky 
for the patient. F-Calprotectin is a marker of intestine inflammation: as IBD patients 
exhibit levels higher than the general population and IBS patients, F-Calprotectin can 
be used to rule out IBD. The only CE evaluation on F-Calprotectin has been published 
by NHS (CEP09041, 2010); based on new evidence, we propose a refined model to 
evaluate the CE of F-Calprotectin compared to the standard pre-endoscopic sero-
logic test (CRP+ESR) to distinguish IBD from IBS in the UK and Spain. Methods: 
F-Calprotectin sensitivity (0.96) and specificity (0.96) were evaluated from a meta-
analysis performed in March 2013; CRP+ESR sensitivity (0.35) and specificity (0.73), 
and the costs come from CEP09041. Published HRQoL values for IBD and IBS were 
transformed in QALYs with transfer-to-utility techniques. The outcomes included 
cost savings, cost per QALY. Uncertainty was addressed with a probabilistic sensitiv-
ity analysis. results: Results for UK show that F-Calprotectin is CE with respect 
to CRP+ESR: a) it results in more corrected IBD diagnoses at a lower price (it costs 
113£ and 85€ less per patient); b) it reduces the number of unnecessary endoscopies, 
increasing the number of correctly diagnosed IBD (N= 59) and IBS (N= 195) patients; 
c) it brings about a QALY gain per patient equal to 0.0034QALYs; in the UK, the ICER 
of the CRP+ESR diagnostic strategy is 47,783£ (25,941€ for Spain), falling well outside 
the cost-effectiveness bounds (20,000–30,000£ per additional QALY). conclusions: 
F-Calprotectin is CE to rule out IBD in primary care in UK and Spain.
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Paz S.6, Lizán L.6, Schwander B.7, Dominguez M.uñoz E8
1Hospital General Universitario de Alicante, Alicante, Spain, 2Complejo Hospitalario La Mancha 
Centro, Alcazar de San Juan, Spain, 3Consorci Sanitari de Terrasa, Terrasa, Spain, 4Abbott 
Laboratories, Madrid, Spain, 5Abbott Laboratories, Allschwil, Switzerland, 6Outcomes 10, 
Castellon, Spain, 7AHEAD GmbH, Loerrach, Germany, 8Hospital Universitario de Santiago de 
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objectives: To systematically appraise the literature on the accuracy of four widely 
used tests to diagnose Pancreatic Exocrine Insufficiency (PEI) secondary to chronic 
pancreatitis (CP), gastrointestinal/pancreatic surgery or pancreatic cancer in Spain, 
namely: coefficient of fat absorption (CFA); mixed 13C-triglyceride breath test (MTG); 
fecal elastase-I (FE-I); and serum nutritional markers (SNM). Methods: A system-
atic review of the literature (March, 2013) was performed (MedLine/PubMed, Cochrane 
Library, CRD, MEDION, ARIF, MEDES, IBECS, ISI WOK, SCOPUS), based on the Cochrane 
and NHS Centre for Reviews and Dissemination recommendations for reviewing 
diagnostic test accuracy studies. Expert validation of the review strategy and results 
were achieved by two consensus meetings. results: Out of 13.379 publications, 16 
from the systematic search and 3 from hand-search were reviewed: 11 in CP and 8 
in cancer/surgery patients. Fourteen of these used the secretin/cerulein test as the 
reference standard. According to experts, CFA is the gold standard for PEI diagnosis 
(assumed accuracy 100%). 4 publications using CFA as the reference standard were 
selected: FE-I sensitivity and specificity in 58 CP (cutoff < 218μ g/g) and 40 cancer/
surgery patients (cutoff 200μ g/g) were 68% and 98%, and 91% and 35%, respectively. 
MTG was ≥ 90% sensitive and specific in all populations (63 patients), experts con-
sidered this a good reference standard. Sensitivity and specificity for SNM vs. MTG 
were 80% and 81%, respectively and considered by experts as similarly accurate in 
the cancer/surgery population. conclusions: This is the first systematic review 
to confirm the accuracy of four diagnostic tests for PEI in CP and cancer/surgery 
patients, with the final selection of results being based on expert consensus to 
ensure that the data are representative of Spanish clinical practice. These data, 
together with resource use and cost information from clinical practice will feed an 
economic tool to assess the cost of PEI diagnosis in Spain.
Pgi4
networK meta-analysis of aPProVed Biologic interVentions for tHe 
induction of resPonse in ulceratiVe colitis
Chen M.1, Black C.M.2, Gurunath S.1, Jansen J.P.3, Chaudhary M.A.4, Fan T.5
1Mapi Group, Boston, NJ, USA, 2Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 
Whitehouse Station, NJ, USA, 3Mapi / Tufts University School of Medicine, Boston, MA, USA, 
4Merck Research Laboratories, North Wales, PA, USA, 5Merck & Co. Inc., Whitehouse Station, NJ, 
USA
objectives: To evaluate the comparative efficacy of approved biologic treatments 
for ulcerative colitis (UC), with a focus on golimumab(GOL), adalimumab(ADA), and 
infliximab(IFX) in the induction periods of clinical trials. Methods: A systematic 
